Join to View Full Profile
22 Bramhall StPortland, ME 04102
Phone+1 207-662-0111
Fax+1 540-982-0103
Dr. Inhorn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1985 - 1988
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1982 - 1985
Johns Hopkins University School of MedicineClass of 1982
Certifications & Licensure
ME State Medical License 2019 - 2026
VA State Medical License 1988 - 2026
WV State Medical License 1989 - 2006
IN State Medical License 1985 - 2003
IL State Medical License 1982 - 1987
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting Start of enrollment: 2010 Dec 02
- Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
Publications & Presentations
PubMed
- 16 citationsObinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.Jeff P. Sharman, Andres Forero-Torres, Luciano J. Costa, Ian W. Flinn, Lowell Inhorn
Leukemia & Lymphoma. 2019-03-21 - 14 citationsPixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.David Belada, Pencho Georgiev, Shaker R. Dakhil, Lowell F Inhorn, David Andorsky
Future Oncology. 2016-04-20 - 10 citationsA RAS oncogene imparts growth factor independence to myeloid cells that abnormally regulate protein kinase C: a nonautocrine transformation pathway.Boswell Hs, T. S. Nahreini, Burgess Gs, Arun Srivastava, Theodore G. Gabig
Experimental Hematology. 1990-06-01
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
